Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.7K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Master Transcription Regulators02:23

Master Transcription Regulators

7.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.9K
Epigenetic Regulation01:46

Epigenetic Regulation

34.0K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS.

bioRxiv : the preprint server for biology·2026
Same author

A dietary switch promotes sensory neuron-dependent cancer-associated cachexia.

Science (New York, N.Y.)·2026
Same author

Autophagy Inhibition Reprograms the Tumor Microenvironment of Pancreatic Cancer to Promote Macrophage Phagocytosis of Tumor Cells.

Cancer research·2026
Same author

Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS<sup>G12C</sup> suppresses PI3Kα and leads to potent tumor inhibition.

bioRxiv : the preprint server for biology·2026
Same author

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.

bioRxiv : the preprint server for biology·2026
Same author

PARP1 suppression drives ROS resistance in aneuploid cancer cells.

Molecular cell·2026

Related Experiment Video

Updated: Feb 25, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.8K

MUC1-C activates EZH2 expression and function in human cancer cells.

Hasan Rajabi1, Masayuki Hiraki1, Ashujit Tagde1

  • 1Dana-Farber Cancer Institute Harvard Medical School Boston, Boston, MA, 02215, USA.

Scientific Reports
|August 9, 2017
PubMed
Summary

Targeting the MUC1-C oncoprotein downregulates EZH2 expression and function in cancer. This reveals a novel mechanism where MUC1-C activates EZH2, impacting histone methylation and tumor suppressor gene activity.

More Related Videos

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.8K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.5K

Related Experiment Videos

Last Updated: Feb 25, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.8K
Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.8K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.5K

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Enhancer of Zeste Homolog 2 (EZH2) is a histone methyltransferase overexpressed in cancers, correlating with poor prognosis.
  • Mucin 1 Cell Cortex (MUC1-C) is an oncoprotein overexpressed in carcinomas, implicated in epigenetic regulation.
  • The regulatory relationship between MUC1-C and EZH2 in cancer remains uncharacterized.

Purpose of the Study:

  • To investigate the role of MUC1-C in regulating EZH2 expression and function in human carcinoma cells.
  • To elucidate the molecular mechanisms by which MUC1-C influences EZH2 activity.

Main Methods:

  • Utilized human carcinoma cell lines to assess the impact of targeting MUC1-C.
  • Investigated EZH2 promoter activity, MUC1-C binding to EZH2, and association with target gene promoters (CDH1, BRCA1).
  • Assessed global and promoter-specific H3K27 trimethylation (H3K27me3) levels and tumor suppressor gene expression.

Main Results:

  • Targeting MUC1-C downregulated EZH2 and other Polycomb Repressive Complex 2 (PRC2) components.
  • MUC1-C activated the EZH2 promoter via the pRB→E2F pathway and an NF-κB p65 enhancer.
  • MUC1-C directly bound EZH2 and associated with it on the CDH1 and BRCA1 promoters, leading to decreased H3K27me3 and BRCA1 activation.

Conclusions:

  • MUC1-C plays a previously unreported role in activating EZH2 expression and function in cancer cells.
  • MUC1-C contributes to epigenetic dysregulation in cancer by promoting EZH2 activity.
  • Targeting MUC1-C represents a potential therapeutic strategy to inhibit EZH2 in carcinomas.